🔴 Tvardi Therapeutics is trading 5.7% down — no clear company-specific catalyst identified

Tvardi Therapeutics is trading 5.7% lower at $1.17, with no clear company-specific announcement identified to explain the October 2 move.

• The broader market gained, but there is no clear evidence its sentiment explains the stock-specific decline.
• The investor-relations page lists its latest press releases in August, with no October 2 release shown.
• Trading volume was reported near average earlier in the session, though that external feed’s price differs from the supplied live price context.